Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

The Path to Product Inclusion in Clinical Guidelines: Strategies for Success

Product Code:
400200152
Publication date:
January 2013
Format:
PDF
Pages:
49
Price:
£345

Clinical guidelines are taking hold in the practice of medicine. Though not always voluntarily followed in real-world patient care, they increasingly form the basis of formulary and reimbursement decisions, as well as the continuing medical education (CME) materials used by physicians.

In this guidelines-centric culture, it is more imperative than ever for drugs to be on the guidelines, and also harder than ever to influence the data that determines them.

Best practices around clinical guideline development call for independent analysis of raw data – untainted by financial gain or academic prestige.

In this tightly controlled and highly sensitive environment, what can Pharma do to maximise the credibility and visibility of its products? If you’ve looked for information about clinical guidelines written with Pharma in mind, you’ve probably ended your search empty-handed.

The sensitive nature of the Pharma-clinical guideline relationship has made it difficult for Pharma to talk about this important topic.

This FirstWord Dossier report addresses this critical knowledge gap, and has been designed to get Pharma up to speed with the complexities of clinical guideline development and adherence, and to be prepared for future trends. The report also provides practical insights on how to increase visibility of medicines, even in an area that is beyond commercial influence.

Key features of The Path to Product Inclusion in Clinical Guidelines: Strategies for Success include:

  • Exclusive insights from industry experts
  • Clear documentation of how Pharma’s footprint is being eliminated from the appraisal of evidence
  • Explanation of the critical importance of clinical guidelines in rationalising the use of medicine
  • Cautionary tales of challenges to the guidelines
  • Detailed description of the latest standardised methods and best practices for research and guideline development worldwide (e.g., CONSORT, PRISMA, AGREE)
  • Up-to-date findings on adherence to guidelines
  • Handy global list of websites for referencing clinical guidelines

Key Benefits

In spite of most companies’ reluctance to speak on this subject, FirstWord has sourced illuminating commentary from Big Pharma representatives and prominent clinical guidelines experts. This report will help you to:

  • Understand and effectively respond to the profound cultural shift towards evidence-based healthcare
  • Know how to gain a tactical advantage by considering a product’s place in clinical guidelines before development starts
  • Receive expert advice on how to position data and products for better visibility
  • Get up to speed with the new concept of “activation of evidence”
  • Hear how the full and open disclosure of clinical trial results is likely to become the norm rather than the exception
  • Learn how clinical guidelines are moving from demonstrating best practice to best value

The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
answers key questions including:
  • What can Pharma do to make best use of the evidence they have?
  • What do opinion leaders want from Pharma?
  • What are the major trends in guideline development, and how can we ensure that our scientific messaging is in line with that thinking?
  • Why don’t doctors always follow the guidelines?
  • How holy is the holy grail of evidence-based medicine?

Selected Quotes

“The perspective of people who know how to manage data and the pitfalls would be valuable on [guideline] committees and I think they would also mitigate the influences where there are conflicts of interest,” Dr. Philip Mackowiak, chief of the Medical Care Clinical Centre, VA Maryland Health Care System

“[The PPSA’s policy on KOL payments] suggests that anybody who works with a pharmaceutical company is somehow doing something wrong. We are not going to move forward. We are not going to advance medical science ” Dr. Maurie Markman, senior vice president of clinical affairs, Cancer Treatment Centres of America

“The only way forward is to look at the very early phase development work, which is about defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved